Identification of Serum Biomarkers to Monitor Therapeutic Response in Intestinal-Type Gastric Cancer

• Published in: International journal of molecular sciences Vol. 25; no. 6; p. 3129
• Main Authors: Dagley, Laura F, Yousef, Jumana, Preaudet, Adele, Loving, Andrea, Webb, Andrew I, Ernst, Matthias, Putoczki, Tracy L
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2024; MDPI
• Subjects: Animals; Antigens; Biological markers; biomarker; Biomarkers; Biomarkers, Tumor; Biotechnology industry; Cancer; Cancer therapies; Care and treatment; Clinical medicine; Cytokine Receptor gp130 - metabolism; Cytokines; Development and progression; Diagnosis; Disease; Ethylenediaminetetraacetic acid; Gastric cancer; Glycoproteins; Health aspects; Immunoglobulins; Interleukin-11; Interleukins; intestinal-type gastric cancer; Mice; mouse model; Protein expression; Proteins; Proteomics; Signal Transduction - physiology; Stomach cancer; Stomach Neoplasms - pathology; Success; Tumors; Australia; intestinal-type gastric cancer; mouse model; proteomics; biomarker; Interleukin-11
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25063129

There are a limited number of clinically useful serum biomarkers to predict tumor onset or treatment response in gastric cancer (GC). For this reason, we explored the serum proteome of the murine model of intestinal-type gastric cancer (IGC). We identified 30 proteins with significantly elevated expression in early IGC and 12 proteins that were significantly elevated in late IGC compared to age- and gender-matched wild-type mice. Within these signatures, there was an overlap of 10 proteins commonly elevated in both early- and late-stage disease. These results highlight the potential to identify serum biomarkers of disease stage. Since IGC in the model can be reversed following therapeutic inhibition of Interleukin (IL)-11, we explored whether the protein signatures we identified could be used to monitor tumor regression. We compared two different therapeutic modalities and found 5 proteins to be uniquely differentially expressed between control animals and animals halfway through treatment, with 10 differentially expressed at the end of treatment. Our findings highlight the potential to identify reliable biomarkers to track IGC tumor regression in response to treatment.